SCHEMBL6852773

SCHEMBL6852773

CNCCCCCOc1cccc2ccccc12

nearest known ligand 0.97

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 2/20 0.97
▸ HRH1 P35367 1/20 0.88
▸ HTR1B P28222 11/20 0.79
▸ HTR1D P28221 2/20 0.79
▸ NR2E1 Q9Y466 1/20 0.61
▸ KCNA3 P22001 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ TP53 P04637 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128162 0.93 SLC6A4 (1.00) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL30756664 0.88 HTR1B (1.00) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL6846952 0.88 HTR1B (1.00) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902840 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902855 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902853 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902849 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902852 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902854 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1
SCHEMBL16902863 0.86 KCNA3 (0.79) SLC6A4HRH1HTR1BHTR1DNR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 — — US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 — — US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 — — EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 — — US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 — — US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 SLC6A4 841/4885HRH1 4/4885HTR1B 114/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 SLC6A4 841/4885HRH1 4/4885HTR1B 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback